Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC) Stock Price, Analysis & Data
| Bid | 8.9 |
| Market Cap | 430.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.54M |
| Beta | 0.26 |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.33 |
| P/B (ttm) | 2.35 |
| P/S (ttm) | n/a |
| Earnings Date | Sep 22, 2026 |
| Ask | 16.01 |
| Volume | 6,000 |
| Avg. Volume (20D) | 124,382 |
| Open | 12.40 |
| Previous Close | 12.34 |
| Day's Range | 12.40 - 12.77 |
| 52-Week Range | 9.85 - 16.76 |
| Analyst | Strong Buy |
| Price Target | 24.5 (95.37%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The com...
Financial Performance
In 2025, Benitec Biopharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -37.92M, an increase of 74.32%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for BNTC stock is "Strong Buy". The 12-month stock price forecast is 24.5, which is upside of 95.37% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
